Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul:65:101171.
doi: 10.1016/j.neo.2025.101171. Epub 2025 May 3.

Establishment of patient-derived 3D in vitro models of sarcomas: literature review and guidelines on behalf of the FORTRESS working group

Affiliations
Review

Establishment of patient-derived 3D in vitro models of sarcomas: literature review and guidelines on behalf of the FORTRESS working group

Lore De Cock et al. Neoplasia. 2025 Jul.

Abstract

Sarcomas are a large family of rare and heterogeneous mesenchymal tumors, which respond poorly to available systemic treatments. Translation of preclinical findings into clinical applications has been slow, limiting improvements in patients' outcomes and ultimately highlighting the need for a better understanding of sarcoma biology to develop more effective, subtype-specific therapies. To this end, reliable preclinical models are crucial, but the development of 3D in vitro sarcoma models has been lagging behind that of epithelial cancers. This is primarily due to the rarity and heterogeneity of sarcomas, and lack of widespread knowledge regarding the optimal growth conditions of these in vitro models. In this review, we provide an overview of currently available sarcoma tumoroid models, together with guidelines and suggestions for model development and characterization, on behalf of the FORTRESS (Forum For Translational Research in Sarcomas) international research working group on 3D sarcoma models.

Keywords: 3D in vitro models; Patient-derived preclinical models; Sarcoma; Tumoroids.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Overview of advantages (+) and disadvantages (-) of the most commonly used patient-derived preclinical sarcoma models. Image was created in BioRender (De Cock, L. (2025) https://BioRender.com/o16p656).

Similar articles

Cited by

References

    1. Burningham Z., Hashibe M., Spector L., Schiffman J.D. The epidemiology of sarcoma. Clin. Sarcoma Res. 2012;2(1):14. - PMC - PubMed
    1. WHO Classification of Tumours Editorial Board . 5th ed. International Agency for Research on Cancer; Lyon (France): 2020. Soft tissue and bone tumours, WHO classification of tumours series. vol 3.
    1. Italiano A., Mathoulin-Pelissier S., Cesne A.L., Terrier P., Bonvalot S., Collin F., et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117(5):1049–1054. - PubMed
    1. Vibert J., Watson S. The Molecular Biology of Soft Tissue Sarcomas: Current Knowledge and Future Perspectives. Cancers (Basel) 2022;14(10):2548. - PMC - PubMed
    1. Sanchez-Fdez A., Sharma A.K., Tiriac H., Sicklick J.K. Patient-Derived Sarcoma Organoids Offer a Novel Platform for Personalized Precision Medicine. Ann. Surg. Oncol. 2022;29(12):7239–7241. - PMC - PubMed

Publication types